PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 December; 4(4): 434–439.
Published online 2003 August 19. doi:  10.1208/pt040455
PMCID: PMC2750648

Biodegradation and in vivo biocompatibility of rosin: a natural film-forming polymer

Abstract

The specific aim of the present study was to investigate the biodegradation and biocompatibility characteristics of rosin, a natural film-forming polymer. Both in vitro as well as in vivo methods were used for assessment of the same. The in vitro degradation of rosin films was followed in pH 7.4 phosphate buffered saline at 37°C and in vivo by subdermal implantation in rats for up to 90 days. Initial biocompatibility was followed on postoperative days 7, 14, 21, and 28 by histological observations of the surrounding tissues around the implanted films. Poly (DL-lactic-co-glycolic acid) (PLGA) (50[ratio]50) was used as reference material for biocompatibility. Rate and extent of degradation were followed in terms of dry film weight loss, molecular weight (MW) decline, and surface morphological changes. Although the rate of in vitro degradation was slow, rosin-free films showed complete degradation between 60 and 90 days following subdermal implantation in rats. The films degraded following different rates, in vitro and in vivo, but the mechanism followed was primarily bulk degradation. Rosin films demonstrated inflammatory reactions similar to PLGA, indicative of good biocompatibility. Good biocompatibility comparable to PLGA is demonstrated by the absence of necrosis or abscess formation in the surrounding tissues. The study provides valuable insight, which may lead to new applications of rosin in the field of drug delivery.

Keywords: biodegradation, biocompatibility, rosin

Full Text

The Full Text of this article is available as a PDF (826K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Park H, Park K. Biocompatibility issues of implantable drug delivery systems. Comprehensive Biotechnology. 1996;13:1770–1776. [PubMed]
2. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled drug delivery systems for proteins based on poly(lactic-coglycolic acid) microspheres. Pharm Res. 1991;8:713–720. doi: 10.1023/A:1015841715384. [PubMed] [Cross Ref]
3. Kissel T, Birch Z, Bantle S, Lancranjan I, Nimmerfall F, Vit F. Parenteral depot systems on the basis of biodegradable polymers. J Control Release. 1991;16:27–42. doi: 10.1016/0168-3659(91)90028-C. [Cross Ref]
4. Chasin M, Lewis D, Langer R. Poly(anhydrides) for controlled release. Biopharm Manufacturing. 1998;1:33–46.
5. Peicuch JF, Fedorka NJ. Results of soft tissue surgery over implanted Replamineform hydroxyapatile. J Oral Maxillofac Surg. 1984;41:801–806. doi: 10.1016/S0278-2391(83)80047-0. [PubMed] [Cross Ref]
6. Ratner BB, Horbelt T, Hoffman AS, Mallschka SD. Cell adhesion to polymeric materials: implication with respect to biocompatibility. J Biomed Mater Res. 1975;9:407–423. doi: 10.1002/jbm.820090505. [PubMed] [Cross Ref]
7. Pathak YV, Dorle AK. Study of rosin esters as coating materials for controlled release of drugs. J Control Release. 1987;5:67–72. doi: 10.1016/0168-3659(87)90038-1. [Cross Ref]
8. Mandaogade PM, Satturwar PM, Fulzele SV, Gogte BB, Dorle AK. Rosin derivatives: novel film forming materials for controlled drug delivery. React Funct Polym. 2002;50:233–242. doi: 10.1016/S1381-5148(01)00117-1. [Cross Ref]
9. Sheorey DS, Dorle AK. Release kinetics of drugs from rosin glycerol ester microcapsules prepared by solvent evaporation. J Microencapsul. 1991;8:243–247. doi: 10.3109/02652049109071492. [PubMed] [Cross Ref]
10. Puranik PK, Dorle AK. Study of abietic acid glycerol derivatives as microencapsulating materials. J Microencapsul. 1991;8:247–252. doi: 10.3109/02652049109071493. [PubMed] [Cross Ref]
11. Hemmings PW, Long W. Rosin ester derivative as surfactant. US Patent 5 552 519. July 3, 1996.
12. Wolf FR. Chewing gum containing Cuphea oil. US Patent 6 077 547. June 20, 2000.
13. Schakenraad JM, Nieuwenhuis P, Molenaar I, Helder J, Dijkstra PJ, Feijen J. In vivo and in vitro degradation of glycine/DL-lactic acid copolymers. J Biomed Mater Res. 1989;23:1271–1288. doi: 10.1002/jbm.820231105. [PubMed] [Cross Ref]
14. Suggs LJ, Krishnan RS, Garcia CA, Peter SJ, Anderson JM, Mikos AG. In vitro and in vivo degradation of poly(propylene fumarate-co-ethylene glycol) hydrogels. J Biomed Mater Res. 1998;42:312–320. doi: 10.1002/(SICI)1097-4636(199811)42:2<312::AID-JBM17>3.0.CO;2-K. [PubMed] [Cross Ref]
15. Lu L, Garcia CA, Mikos AG. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res. 1999;46:236–244. doi: 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F. [PubMed] [Cross Ref]
16. Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly (3-hydroxybutyrate) (PHB) and poly(3-hydroxybutyrate-cp-3-hydroxyvalerate) (PHB/VA) J Biomed Mater Res. 1993;27:1135–1148. doi: 10.1002/jbm.820270904. [PubMed] [Cross Ref]
17. Ibim SM, Uhrich KE, Bronson R, Amin S, Langer RS, Laurencin CT. Poly(anhydride-co-imides): in vivo biocompatibility in a rat model. Biomaterials. 1998;19:941–951. doi: 10.1016/S0142-9612(98)00019-2. [PubMed] [Cross Ref]
18. Goissis G, Junior EM, Marcantonio RA, Lia RC, Cancian DCJ, Carvalho W. Biocompatibility studies of anionic collage membranes with different degree of glutaraldehyde cross-linking. Biomaterials. 1999;20:27–34. doi: 10.1016/S0142-9612(97)00198-1. [PubMed] [Cross Ref]
19. Smith R, Oliver C, Williams DF. The enzymatic degradation of polymers in vitro. J Biomed Mater Res. 1987;21:991–1003. doi: 10.1002/jbm.820210805. [PubMed] [Cross Ref]
20. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials. 1996;17:103–114. doi: 10.1016/0142-9612(96)85755-3. [PubMed] [Cross Ref]
21. Tokiwa Y, Suzuki T. Hydrolysis of polyesters by lipases. Nature. 1977;270:76–78. doi: 10.1038/270076a0. [PubMed] [Cross Ref]
22. Ali SAM, Doherty PJ, Williams DF. Molecular biointeractions of biomedical polymers with extracellular exudates and inflammatory cells and their effects on biocompatibility in vivo. Biomaterials. 1994;15:779–785. doi: 10.1016/0142-9612(94)90032-9. [PubMed] [Cross Ref]
23. Tracy MA, Ward KL, Firouzabadian L, Wang Y, Dong N, Quian R, Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20:1057–1062. doi: 10.1016/S0142-9612(99)00002-2. [PubMed] [Cross Ref]
24. Marchant RE. The cage implant system for determining in vivo biocompatibility of medical device materials. Fundam Appl Toxicol. 1989;13:217–227. doi: 10.1016/0272-0590(89)90258-3. [PubMed] [Cross Ref]
25. Collier T, Tan J, Shive M, Hasan S, Hiltner A, Anderson J. Biocompatibility of poly(ether-urethrane urea) containing dehydroepiandrosterone. J Biomed Mater Res. 1993;41:192–201. doi: 10.1002/(SICI)1097-4636(199808)41:2<192::AID-JBM3>3.0.CO;2-D. [PubMed] [Cross Ref]
26. Anderson JM. In vivo biocompatibility of implantable delivery systems and biomaterials. Eur J Pharm Biopharm. 1994;40:1–8.
27. Marchant R, Hiltner A, Hamlin C, Rabinovitch A, Slobodkin R, Anderson JM. In vivo biocompatibility studies, I: the cage implant system and a biodegradable hydrogel. J Biomed Mater Res. 1983;15:889–902. [PubMed]
28. Spenlehauer G, Vert M, Benoit JP, Boddaert A. In vitro and in vivo degradation of poly(DL-lacide/glycolide) type microspheres made by solvent evaporation method. Biomaterials. 1992;13:594–600. doi: 10.1016/0142-9612(92)90027-L. [PubMed] [Cross Ref]
29. Chu CC, Williams DF. The effect of gamma irradiation on enzymatic degradation of polyglycolic acid absorbable suture. J Biomed Mater Res. 1983;17:1029–1040. doi: 10.1002/jbm.820170612. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists